Thrombus Classifications

Topaz, On; Topaz, Allyne

doi:10.1016/b978-0-12-812615-8.00012-0

Cited by 4 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given that we previously identified a significant improvement in MBG induced by ELCA [ 13 ], an improvement in microcirculation is the most probable cause for the decrease in in-hospital mortality rate. In the previous study, it was reported that “platelet stunning” effect is dose dependent and most pronounced at high levels of laser emission such as 60 mJ/mm 2 [ 6 ]. However, approximately 10% of the cases experienced deterioration of the TIMI flow grade when the level gradually increased from a low level to a high level of laser emission.…”

Section: Discussionmentioning

confidence: 99%

“…Consequently, another capable technology for improved thrombus removal is highly needed [ 5 ]. ELCA is one of the most effective treatments to remove intracoronary thrombi [ 6 ]. Laser atherectomy in AMI presents several advantages: rapid elimination of the thrombus with vaporization, removal of procoagulant reactants, diminution of the risk of distal embolization, and reduction of platelet aggregation promotors (“stunned platelets” phenomenon) [ 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of small diameter and low level of emission laser coronary atherectomy in patients with acute myocardial infarction

et al. 2021

View full text Add to dashboard Cite

Excimer laser coronary atherectomy (ELCA) is an effective treatment to remove intracoronary thrombi. In the present study, we compared in-hospital mortality in patients with acute myocardial infarction (AMI) who underwent conventional treatment and conventional treatment plus ELCA. Among 656 patients who were admitted to our hospital through the Tokyo CCU Network, 104 patients with AMI who were treated by percutaneous coronary intervention between January 2013 and December 2016 met inclusions criteria and underwent conventional treatment with ELCA (ELCA group) and 89 underwent conventional treatment alone (conventional group). We retrospectively evaluated in-hospital mortality within 30 days and used propensity score (PS) matching to reduce assignment bias and multivariate analysis to detect the predictors of in-hospital mortality. In-hospital mortality rate was significantly lower in the ELCA group before and after PS matching (2.9% vs. 13.5%, p = 0.006 before PS matching, and 2.8% vs. 14.1%, p = 0.016 after PS matching). After PS matching, β-blocker or statins use, incidence of shock, Killip classification, and door-to-balloon time were not significantly different. A multivariate logistic regression analysis identified ELCA, dyslipidemia, shock, and left ventricular ejection fraction as independent predictors of in-hospital mortality (odds ratio (OR), 0.147, 95% confidence interval [CI], 0.022–0.959, p = 0.045; OR, 0.077, 95% CI, 0.007–0.805, p = 0.032; OR, 6.494, 95% CI, 1.228–34.34, p = 0.028; OR, 0.890, 95% CI, 0.828–0.957, p = 0.002, respectively). Our data indicate that ELCA with the small diameter and low level emission may reduce the in-hospital mortality compared to conventional methods in patients with AMI in drug-eluting stent era.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Impact of small diameter and low level of emission laser coronary atherectomy in patients with acute myocardial infarction

et al. 2021

View full text Add to dashboard Cite

show abstract

“…To demonstrate, the thrombosis of an artery may cause a stroke in the brain or myocardial infarction in the heart [26]. The main three causes of thrombosis are vascular injury, stasis, and hypercoagulability [27]. The clot either be a thrombus that extends to the wall but does not close the blood vessel and is known as the mural thrombus.…”

Section: Theorymentioning

confidence: 99%

Modeling of Nano-carriers for Vascular-targeted Delivery for Blood Clots Treatment

Yahya

Eltayeb

2020

Preprint

View full text Add to dashboard Cite

AbstractNanoparticles have become one of the emerging and promising technologies that revolutionized the medical field’s future on which has received much attention from the scientific community and researchers. Nanotechnology-based targeted drug delivery has a high capacity for loading large amounts of anticoagulants drug to dissolve clots in a safe manner without affecting healthy blood vessels. This paper seeks to provide a better understanding of both the anticoagulant drug release process and the coagulation eliminating process by simulating each process using chemical reaction engineering, moving mesh, and convection-diffusion equation modules. This study adds to a growing corpus of research showing that nanotechnology empowers in treating blood clots within 2-4 hours. In addition, these results cast a new light on a better understanding of the anticoagulation drug diffusion from both spheres and multiply-twinned nanoparticles besides the reduction of clots growth and how it dissolved over time.

show abstract

“…[5,6] Current treatment and diagnosis of thrombosis have some limitations including the use of radiation, invasiveness, low specificity, substantial economic burden, and side effects such as potentially deadly bleeding. [6][7][8][9][10][11][12][13] Some of the emerging non-invasive imaging techniques for the accurate diagnosis of CVDs include magnetic resonance imaging (MRI) and photoacoustic imaging (PAI). [14,15] The main advantages of MRI and PAI over conventional techniques include higher tissue penetration depth, high spatial resolution, the lack of ionizing radiation, non-invasiveness, and the ability to track treatment progression.…”

mentioning

confidence: 99%

A Spiky Silver‐Iron Oxide Nanoparticle for Highly Efficient Targeted Photothermal Therapy and Multimodal Imaging of Thrombosis

Vazquez-Prada

Moonshi

et al. 2023

Small

View full text Add to dashboard Cite

Thrombosis and its complications are responsible for 30% of annual deaths. Limitations of methods for diagnosing and treating thrombosis highlight the need for improvements. Agents that provide simultaneous diagnostic and therapeutic activities (theranostics) are paramount for an accurate diagnosis and rapid treatment. In this study, silver‐iron oxide nanoparticles (AgIONPs) are developed for highly efficient targeted photothermal therapy and imaging of thrombosis. Small iron oxide nanoparticles are employed as seeding agents for the generation of a new class of spiky silver nanoparticles with strong absorbance in the near‐infrared range. The AgIONPs are biofunctionalized with binding ligands for targeting thrombi. Photoacoustic and fluorescence imaging demonstrate the highly specific binding of AgIONPs to the thrombus when functionalized with a single chain antibody targeting activated platelets. Photothermal thrombolysis in vivo shows an increase in the temperature of thrombi and a full restoration of blood flow for targeted group but not in the non‐targeted group. Thrombolysis from targeted groups is significantly improved (p < 0.0001) in comparison to the standard thrombolytic used in the clinic. Assays show no apparent side effects of AgIONPs. Altogether, this work suggests that AgIONPs are potential theranostic agents for thrombosis.

show abstract

Thrombus Classifications

Cited by 4 publications

References 41 publications

Impact of small diameter and low level of emission laser coronary atherectomy in patients with acute myocardial infarction

Impact of small diameter and low level of emission laser coronary atherectomy in patients with acute myocardial infarction

Modeling of Nano-carriers for Vascular-targeted Delivery for Blood Clots Treatment

A Spiky Silver‐Iron Oxide Nanoparticle for Highly Efficient Targeted Photothermal Therapy and Multimodal Imaging of Thrombosis

Contact Info

Product

Resources

About